QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.330

CONFIDENTIAL   REDACTED VERSION

        [***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS.

TERM SHEET

        This binding Term Sheet sets forth the agreement of Chiron Corporation
("Chiron"), on the one hand, and F. Hoffmann-La Roche Ltd. and Roche Molecular
Systems, Inc. (collectively, "Roche"), on the other, with respect to the
settlement of their current arbitration relating to royalties ("Arbitration"),
through amendment of the HIV Probe License Agreement by and between the parties
effective as of October 10, 2000 ("Clinical Diagnostics Agreement") and the
Blood Screening HIV Probe License Agreement by and between the parties effective
as of January 1, 2001 ("Blood Screening Agreement," collectively with the
Clinical Diagnostics Agreement, the "Agreements"). Terms not defined in this
Term Sheet have the meanings given to them in the applicable Agreement. This
Term Sheet shall become effective as of September 3, 2004.

1.Definitions:

        a.     "Additional Chiron Patents" means Valid Claims Directed to HIV
that cover the manufacture, use, sale, offer for sale, or importation of a
Product that are contained within all patents and applications, including future
patents or applications, that are based on inventions conceived by CHIRON or its
Affiliates [***] but are not CHIRON Licensed Patents, and are owned by Chiron or
its Affiliates [***].

        b.     "Excluded Party" [***].

        c.     "Limiting Event," with respect to an Agreement, means (i) the
permissible assignment of such Agreement to any Excluded Party, or (ii) any
Roche Affiliate that is involved in the businesses to which such Agreement
relates becoming directly or indirectly controlled by an Excluded Party (control
being defined as set forth in Section 1.2 of such Agreement).

        d.     "Option Products" means Products that are used by or sold to an
End User under circumstances and in jurisdictions, such that in the absence of
the license granted pursuant to Section 2.5 of the Clinical Diagnostics
Agreement, such use or sale would constitute an infringement of a Valid Claim of
the CHIRON Future HIV Sequence Patent Rights.

        e.     "Qualified Product" means Licensed Products sold by Roche or the
Roche portion of the business of an Excluded Party that, prior to a Limiting
Event, Roche had offered for commercial sale or commercially sold or in respect
of which Roche had filed with the Food and Drug Administration a Section 510(k)
Premarket Notification or a Section 515 Premarket Approval and any improvements
of such Licensed Products or modifications thereto after the Limiting Event.

        f.      "Roche Products" means all assays sold by Roche for the
detection, quantitation, genotyping or other analyses of nucleic acid sequences
Directed to HIV ("Purpose") for use in in vitro diagnostics and/or Blood
Screening, including without limitation the following products of Roche:
Amplicor HIV-1 test, v. 1.0; Amplicor HIV-1 Monitor test, v. 1.0; Amplicor HIV-1
Monitor test, v. 1.5; COBAS Amplicor HIV-1 Monitor test, v. 1.5; Ampliscreen
HIV-1 test, v. 1.5; and COBAS Ampliscreen HIV-1 test, v. 1.5; and all versions
of and successors and substitutes therefor.

        g.     "Territory" means the United States, its territories and
possessions, Puerto Rico, Canada, and Mexico.

1

--------------------------------------------------------------------------------

2.The parties hereby irrevocably stipulate as follows:

        a.     The CHIRON Licensed Patents in the Territory are valid and
enforceable;

        b.     The making, use, offer for sale, sale, or importation of any
Roche Product in the Territory, where a CHIRON Licensed Patent has issued and
prior to the expiration of such CHIRON Licensed Patent, would, in the absence of
the licenses granted in the Agreements, as applicable, constitute infringement
of one or more claims of such CHIRON Licensed Patent;

        c.     The license fees and royalty payments set forth in the Agreements
are due to Chiron for sales of the Roche Products in the Territory;

        d.     Roche releases any claims it asserted in the Arbitration (or
arising out of the same facts and circumstances as the claims it asserted in the
Arbitration) that are contrary to the foregoing subsections a, b, and c; and

        e.     Chiron and Roche Molecular Systems, Inc., with the express
authorization of F. Hoffmann-La Roche Ltd., shall, immediately upon approval of
this Term Sheet by Chiron's Board of Directors, execute the stipulation appended
hereto as Exhibit A ("Stipulation") and request that the arbitrator in the
Arbitration enter an award in the Arbitration consistent with such stipulation.
Roche Molecular Systems, Inc. shall thereafter promptly exercise commercially
reasonable efforts to support any steps Chiron may undertake to have such
stipulated arbitration award promptly confirmed by a court of competent
jurisdiction selected by Chiron.

        f.      Nothing in this Term Sheet or the Stipulation shall apply to
claims of the CHIRON Licensed Patents that are not directed to the Purpose; by
way of example but not by way of limitation, Valid Claims of CHIRON Licensed
Patents directed to immunoassays, antigens, antibodies, and/or proteins are
expressly excluded from the terms of this Term Sheet and the Stipulation,
including, without limitation, Sections 2(a) and 2(b), subject to the final
sentence of Section 8(a).

3.Royalty Provisions. The royalty provisions of the Agreements are amended as
follows:

        a.     Clinical Diagnostics Agreement

            i.  All monies already paid to Chiron pursuant to the Clinical
Diagnostics Agreement shall be retained by Chiron and are non-refundable,
including, without limitation, the Ten Million United States Dollars
(USD$10,000,000) U.S. Licensing Fee, any royalties for sales made prior to
January 1, 2001, and any royalties for sales made thereafter [***].

           ii.  For sales in Region I during the period from [***], Earned
Royalties, as defined in Exhibit A, will be modified as follows:

        x.     [***];

        y.     the Minimum Amount/Test set forth in Paragraph 4 of Exhibit A for
the HIV Qualitative Assay field shall be [***]; and

        z.     the Minimum Amount/Test set forth in Paragraph 4 of Exhibit A for
the HIV Quantitative Assay field shall be [***].

          iii.  On or within 10 days following January 1, 2005, Roche shall pay
Chiron Fifty-Two Million United States Dollars (USD52,000,000) in cumulative
Earned Royalties for sales made in Region I after January 1, 2005 and continuing
through the life of the applicable CHIRON Licensed Patent(s). Subject to
Section 5, such payment shall be nonrefundable. Upon this Term Sheet becoming
binding on all of the parties pursuant to Section 10, the definition of "CHIRON
Licensed Patents" in the Clinical Diagnostics Agreement shall be expanded to
include the "Additional Chiron Patents." Subject to Sections 5 and 6, upon the
payment of

2

--------------------------------------------------------------------------------

such amount, nothing further shall be due to Chiron from Roche in consideration
of the licenses granted pursuant to Sections 2.1 and 2.3 of the Clinical
Diagnostics Agreement for sales in Region I of CHIRON Licensed Products made
after January 1, 2005.

          iv.  With respect to CHIRON Future HIV Sequence Patent Rights acquired
by Chiron [***], pursuant to Section 2.5 of the Clinical Diagnostics Agreement,
Chiron agrees to grant such rights to Roche on the following payment terms:

        w.    [***]

        x.     [***]

        y.     Roche's payment obligations for sales of Option Products not
established by subsections w and x shall be [***] and resolved, if necessary,
through the ADR process in accordance with Article 10 of the Clinical
Diagnostics Agreement to determine the terms that are commercially reasonable.

        z.     The terms of the Clinical Diagnostic Agreement shall be modified
as necessary to make such Agreement (i) no less protective of Chiron with
respect to licenses granted pursuant to Section 2.5 than such Agreement is with
respect to the licenses set forth in Sections 2.1 and 2.3, including, by way of
example but not limitation, with respect to payment, reporting, and audit
rights; and (ii) consistent with any agreement under which Chiron acquires any
CHIRON Future HIV Sequence Patent Rights [***], including, by way of example but
not limitation, with respect to payment, reporting, and audit rights.

        b.     Blood Screening Agreement

            i.  All monies already paid to Chiron pursuant to the Blood
Screening Agreement shall be retained by Chiron and are non-refundable,
including, without limitation, any royalties for sales made prior to [***].

           ii.  For sales in Region II during the period from [***], the Earned
Royalty Amounts under Exhibit A will be modified as follows:

        x.     the applicable Earned Royalty Amount for Blood Screening will be
[***]; and

        y.     the applicable Earned Royalty Amount for Plasma Fractionation
will be [***].

          iii.  On or within 10 days following January 1, 2005, Roche shall pay
Chiron Twenty-Six Million United States Dollars (USD26,000,000) in cumulative
Earned Royalties for sales made in Region II after January 1, 2005 and
continuing through the life of the applicable CHIRON Licensed Patent(s). Subject
to Section 5, such payment shall be nonrefundable. Upon this Term Sheet becoming
binding on all of the parties pursuant to Section 10, the definition of "CHIRON
Licensed Patents" in the Blood Screening Agreement shall be expanded to include
the "Additional Chiron Patents." Subject to Sections 5 and 6, upon the payment
of such amount, nothing further shall be due to Chiron from Roche in
consideration of the licenses granted pursuant to Section 2.1 of the Blood
Screening Agreement for sales in Region II of CHIRON Licensed Products made
after January 1, 2005.

4.For purposes of this Term Sheet, a Product shall be deemed to have been sold
in the Region in which the Product is used by an End User resulting in the
Product's consumption, operation, destruction, or loss of activity.

5.a.    At any time on or after January 25, 2005, Roche may notify Chiron that
it desires a partial refund of the payments made pursuant to Sections
3(a)(iii) and 3(b)(iii). Roche's request shall be deemed to have been made on
the Refund Request Date set forth in Exhibit C that immediately follows the
effective date of such notice. Within forty-five (45) days after such Refund
Request

3

--------------------------------------------------------------------------------

Date, Chiron shall refund to Roche the Refund Amounts set forth on Exhibit C for
each Agreement that correspond to such Refund Request Date.

        b.     As of such Refund Request Date, the payments made by Roche
pursuant to Section 3(a)(iii) shall no longer be deemed to be cumulative Earned
Royalties for sales made in Region I after January 1, 2005 under the Clinical
Diagnostics Agreement. Under the Clinical Diagnostics Agreement, from such
Refund Request Date through the Term of the Clinical Diagnostics Agreement:

            i.  the Earned Royalty rate for sales of Licensed Products in the
Territory shall be the Clinical Diagnostics Earned Royalty Rate set forth in
Exhibit C that corresponds to such Refund Request Date;

           ii.  the Minimum Amount/Test set forth in Paragraph 4 of Exhibit A
for the HIV Qualitative Assay field shall be the Minimum Amount/Test for the HIV
Qualitative Assay field set forth in Exhibit C that corresponds to such Refund
Request Date; and

          iii.  the Minimum Amount/Test set forth in Paragraph 4 of Exhibit A
for the HIV Quantitative Assay field shall be the Minimum Amount/Test for the
HIV Quantitative Assay field set forth in Exhibit C that corresponds to such
Refund Request Date.

        c.     As of such Refund Request Date, the payments made pursuant to
Section 3(b)(iii) shall no longer be deemed to be cumulative Earned Royalties
for sales made in Region II after January 1, 2005 under the Blood Screening
Agreement. Under the Blood Screening Agreement, from such Refund Request Date
through the through the Term of the Blood Screening Agreement:

            i.  the applicable Earned Royalty Amount for Blood Screening shall
be the Earned Royalty Amount for Blood Screening set forth in Exhibit C that
corresponds to such Refund Request Date; and

           ii.  the applicable Earned Royalty Amount for Plasma Fractionation
shall be the Earned Royalty Amount for Plasma Fractionation set forth in
Exhibit C that corresponds to such Refund Request Date.

        d.     After October 2, 2006, Roche shall no longer be entitled to any
refund pursuant to this Section 5.

6.Except with respect to products as to which Earned Royalties will be paid at
adjusted rates and amounts pursuant to Section 5 and Exhibit C and products
coming within the terms of Section 7, the most favored nations provisions of the
Agreements shall be of no further force or effect, retrospectively, currently,
or prospectively, with respect to Region I, in the case of the Clinical
Diagnostics Agreement, and Region II, in the case of the Blood Screening
Agreement.

7.a.    Except as provided in Sections 7(b) and 7(c), the royalty provisions of
the Agreements as amended by this Term Sheet will not benefit any Excluded Party
(as defined above) or apply to any products developed by or on behalf of any
Excluded Party. Rather, to the extent any such person or product benefits from
the licenses granted under the Agreements, the royalty provisions set forth in
the Agreements prior to their amendment by this Term Sheet shall apply.

        b.     If a Limiting Event should occur with respect to the Clinical
Diagnostics Agreement, the royalty provisions of this Term Sheet, including,
without limitation, the payments made pursuant to Section 3(a)(iii):

            i.  shall apply in the twelve-month period following such Limiting
Event with respect to, and only with respect to a volume of Qualified Products
having an aggregate selling price equal to [***], and

4

--------------------------------------------------------------------------------

           ii.  shall apply in each of the successive twelve-month periods
following such Limiting Event with respect to, and only with respect to a volume
of Qualified Products [***].

        c.     If a Limiting Event should occur with respect to the Blood
Screening Agreement, the royalty provisions of this Term Sheet, including,
without limitation, the payments made pursuant to Section 3(b)(iii):

            i.  shall apply in the twelve-month period following such Limiting
Event with respect to, and only with respect to a volume of Qualified Products
having an aggregate selling price equal to [***], and

           ii.  shall apply in each of the successive twelve-month periods
following such Limiting Event with respect to, and only with respect to a volume
of Qualified Products [***].

8.            a.    [***].

        b.     [***].

9.Each party shall bear its own fees incurred in connection with the Arbitration
and shall bear half the expenses of the arbitrator.

10.By executing this Term Sheet, each party agrees to be bound by its terms,
subject in the case of Chiron to approval by the Chiron Board of Directors. It
is the current intention of the parties to execute definitive amendments to the
Agreements that will supercede this Term Sheet, however, if such definitive
amendments are not prepared and/or executed by the parties, this Term Sheet will
remain binding upon the parties. This Term Sheet (including the Stipulations in
Exhibits A and B and the chart in Exhibit C hereto, which are incorporated
herein by reference), the Agreements, and the Settlement Agreement effective as
of October 10, 2000 constitute the complete agreement between the parties and
supersede all prior or contemporaneous agreements or representations, written or
oral, concerning the subject matter of this Term Sheet. No party shall rely on
any oral or written representation other than as expressly set forth herein.
This Term Sheet and all matters arising out of or relating to this Term Sheet
shall be interpreted and enforced under the laws of the State of New York. The
provisions of Section 9 of the Settlement Agreement effective as of October 10,
2000 shall apply to any dispute arising out of or relating to this Term Sheet.

11.Each party may issue a press release disclosing the existence of this Term
Sheet. The terms of this Term Sheet and the definitive agreements based on this
Term Sheet ("Terms") will be "Information" of both parties pursuant to Article 8
of the Clinical Diagnostics Agreement. Notwithstanding the foregoing, (i) the
Terms shall be expressly subject to Section 8.4 of the Clinical Diagnostics
Agreement and (ii) Chiron may disclose such Terms to [***], provided that the
recipient of such disclosure has agreed to confidentiality obligations
applicable to the Terms no less restrictive than those contained in Article 8 of
the Clinical Diagnostics Agreement.

12.This Section 12 shall be immediately binding on each party upon execution of
this Term Sheet by all of Chiron, Roche Molecular Systems, Inc., and F.
Hoffmann-La Roche Ltd. At such time, each of Chiron and Roche Molecular
Systems, Inc. shall execute the Renewed Stipulation Re Delayed

5

--------------------------------------------------------------------------------

Rendering of Award appended hereto as Exhibit B and promptly submit such
stipulation to the arbitrator in the Arbitration.

AGREED TO AND ACCEPTED BY:    
Chiron Corporation
 
 
By:
 
/s/  JEKENT      
 
     

--------------------------------------------------------------------------------

    Date:   Sept. 3, 2004        

--------------------------------------------------------------------------------

    AGREED TO AND ACCEPTED BY:    
F. Hoffmann-La Roche Ltd.
 
 
By:
 
/s/  HEINO VON PRONDZYNSKI      
 
     

--------------------------------------------------------------------------------

        /s/  ROBERT YATES              

--------------------------------------------------------------------------------

    Date:   3 Sept 04        

--------------------------------------------------------------------------------

    AGREED TO AND ACCEPTED BY:    
Roche Molecular Systems, Inc.
 
 
By:
 
/s/  H. DREISMANN      
 
     

--------------------------------------------------------------------------------

    Date:   September 3, 2004        

--------------------------------------------------------------------------------

   

6

--------------------------------------------------------------------------------

CONFIDENTIAL   REDACTED VERSION

EXHIBIT A

BEFORE THE HONORABLE
CHARLES B. RENFREW, ARBITRATOR

IN THE MATTER OF THE ARBITRATION
  
BETWEEN
  
CHIRON CORPORATION,    
Claimant
 
STIPULATED ARBITRATION AWARD
AND
 
ROCHE MOLECULAR SYSTEMS, INC.,
 
 
Respondent

 
 

Stipulation

        Chiron Corporation and Roche Molecular Systems, Inc., on behalf of
themselves and their affiliates, hereby irrevocably stipulate as follows:

1."Agreements" means the HIV Probe License Agreement by and between the parties
effective as of October 10, 2000 and the Blood Screening HIV Probe License
Agreement by and between the parties effective as of January 1, 2001;

2."Blood Screening" means the commercial use of products that detect nucleic
acid sequence(s) for: (a) the screening of blood, plasma or blood components
intended for transfusion or for use in blood products (e.g., without limitation,
immunoglobulins); or (b) confirmatory or supplemental testing of the same
samples otherwise screened for purposes described in (a);

3."Directed to HIV" means that the claim or technology in question is directed
to methods, compositions, reagents or kits specifically for use in nucleic
acid-based diagnostic assays for the detection of HIV nucleic acid sequence(s),
or specifically for use in the manufacture of any compositions or reagents for
use in, or manufacture of nucleic acid-based diagnostic assays for detection of
HIV nucleic acid sequence(s) (excluding, for example, polymerase chain reaction
claims and technology and other methods for detection of nucleic acid
sequence(s) generally which involve nucleic acid amplification). The terminology
"specifically for use" as used in this definition, is intended to exclude
inventions suitable for use with viruses or analytes other than HIV (including
by way of example and not by way of limitation, inventions relating to
polymerase chain reaction, or assay formats, improved expression systems,
detectable labels, instrumentation, packaging and the like), which shall not be
considered "specifically for use" in HIV detection as contemplated by this
definition and shall therefore not be considered as "Directed to HIV" hereunder;

4."HIV" means any viral isolate of the human immunodeficiency virus classified
as HIV by the International Committee on the Taxonomy of Viruses (or any body
that replaces such Committee) or any subtype of such isolate and further
includes any isolate that is at least forty percent (40%) homologous to any such
isolate and of the same genomic type and substantially the same genomic

7

--------------------------------------------------------------------------------

organization, any isolate that has a genome that either hybridizes to or is
substantially identical to any such isolate or its compliment, and any defective
or modified form of any of the above isolates;

5."Patent" means U.S. Patent No. 6,531,276 B1;

6."Roche Products" means all assays sold by Roche Molecular Systems, Inc. for
the detection, quantitation, genotyping or other analyses of nucleic acid
sequences Directed to HIV for use in in vitro diagnostics and/or Blood
Screening, including without limitation the following products of Roche
Molecular Systems, Inc.: Amplicor HIV-1 test, v. 1.0; Amplicor HIV-1 Monitor
test, v. 1.0; Amplicor HIV-1 Monitor test, v. 1.5; COBAS Amplicor HIV-1 Monitor
test, v. 1.5; Ampliscreen HIV-1 test, v. 1.5; and COBAS Ampliscreen HIV-1 test,
v. 1.5; and all versions and successors and substitutes therefor;

7.The Patent is valid and enforceable;

8.The making, use, offer for sale, sale, or importation into the United States
of any Roche Product would, in the absence of the licenses granted in the
Agreements, as applicable, constitute infringement of one or more claims of the
Patent;

9.The license fees and royalty payments set forth in the Agreements are due to
Chiron for sales of the Roche Products in the United States;

10.Roche Molecular Systems, Inc., on behalf of itself and its affiliates,
releases any claims it asserted in the Arbitration (or arising out of the same
facts and circumstances as the claims it asserted in the Arbitration) that are
contrary to the foregoing Sections 7, 8, and 9; and

11.The parties hereby request that the Arbitrator enter an award in the
above-captioned Arbitration consistent with the forgoing stipulation. Roche
Molecular Systems, Inc. shall thereafter promptly exercise commercially
reasonable efforts to support any steps Chiron may undertake to have such
stipulated arbitration award promptly confirmed by a court of competent
jurisdiction selected by Chiron.

Date: August    , 2004
 
Agreed:
       

--------------------------------------------------------------------------------

 
 
Stephen S. Rabinowitz
FRIED, FRANK, HARRIS, SHRIVER & JACOBSON LLP
 
 
Charles B. Cohler
PAUL, HASTINGS, JANOFSKY & WALKER LLP
  
Attorneys for Roche Molecular Systems, Inc.
Date: August    , 2004
 
Agreed:
       

--------------------------------------------------------------------------------

 
 
Rachel Krevans
Mathew I. Kreeger
Wesley E. Overson
Lawrence B. Berroya
Peter P. Meringolo
MORRISON & FOERSTER LLP
  
Attorneys for Chiron Corporation

IT IS SO ORDERED.    
By:
 
 
 
     

--------------------------------------------------------------------------------

Hon. Charles B. Renfrew, Arbitrator     Date:            

--------------------------------------------------------------------------------

   

8

--------------------------------------------------------------------------------

CONFIDENTIAL   REDACTED VERSION

EXHIBIT B

BEFORE THE HONORABLE
CHARLES B. RENFREW, ARBITRATOR

IN THE MATTER OF THE ARBITRATION
  
BETWEEN
  
CHIRON CORPORATION,    
Claimant
 
RENEWED STIPULATED RE DELAYED RENDERING OF AWARD
AND
 
ROCHE MOLECULAR SYSTEMS, INC.,
 
 
Respondent

 
 

Stipulation

        Chiron Corporation and Roche Molecular Systems, Inc., on behalf of
themselves and their affiliates, jointly agree and stipulate as follows:

        Notwithstanding Section 9(d)(12) of Settlement Agreement by and between
the parties effective as of October 10, 2000, which requires that the Arbitrator
render an award in this Arbitration together with a decision on the award in
writing ("Award") within seven calendar days following the submission

9

--------------------------------------------------------------------------------

of post-hearing briefs, the parties jointly request that the Arbitrator not
render the Award prior to September 14, 2004, at 4:00 p.m.

Date: August    , 2004
 
Agreed:
       

--------------------------------------------------------------------------------

 
 
Stephen S. Rabinowitz
FRIED, FRANK, HARRIS, SHRIVER & JACOBSON LLP
 
 
Charles B. Cohler
PAUL, HASTINGS, JANOFSKY & WALKER LLP
  
Attorneys for Roche Molecular Systems, Inc.
Date: August    , 2004
 
Agreed:
       

--------------------------------------------------------------------------------

 
 
Rachel Krevans
Mathew I. Kreeger
Wesley E. Overson
Lawrence B. Berroya
Peter P. Meringolo
MORRISON & FOERSTER LLP
  
Attorneys for Chiron Corporation

10

--------------------------------------------------------------------------------

CONFIDENTIAL   REDACTED VERSION

EXHIBIT C

REFUND SCHEDULE AND ADJUSTED ROYALTY RATES

Refund Request Date

--------------------------------------------------------------------------------

  Refund
Amount:
Clinical
Diagnostics
(MM)

--------------------------------------------------------------------------------

  Refund
Amount:
Blood
Screening
(MM)

--------------------------------------------------------------------------------

  Clinical
Diagnostics
Earned
Royalty
Rate

--------------------------------------------------------------------------------

  Minimum
Amount/Test:
HIV
Qualitative
Assay

--------------------------------------------------------------------------------

  Minimum
Amount/Test:
HIV
Quantitative
Assay

--------------------------------------------------------------------------------

  Earned
Royalty
Amount:
Blood
Screening

--------------------------------------------------------------------------------

  Earned
Royalty
Amount:
Plasma
Fractation

--------------------------------------------------------------------------------

2/1/05   [***]   [***]   [***]   [***]   [***]   [***]   [***]
3/31/05
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
6/30/05
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
9/30/05
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
12/31/05
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
3/31/06
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
6/30/06
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
10/2/06
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
12/31/06
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]
 
[***]

11

--------------------------------------------------------------------------------

QuickLinks

Exhibit 10.330

TERM SHEET
EXHIBIT A
EXHIBIT B
EXHIBIT C REFUND SCHEDULE AND ADJUSTED ROYALTY RATES